

Financial news for VCYT dated on 2020-06-09: Veracyte Announces De Novo Classification Request To FDA For nCounter Dx LymphMark Assay

Financial news for VCYT dated on 2020-05-14: UPDATE: CareDx Will Become Exclusive Worldwide Commercialization Partner For Solid Organ Transplant-rejection Tests On Veracyte's Diagnostic Platform

Financial news for VCYT dated on 2020-05-14: CareDx And Veracyte Announce Exclusive Partnership For Transplant Rejection Testing On nCounter System

Financial news for VCYT dated on 2020-05-07: SVB Leerink Maintains Outperform on Veracyte, Raises Price Target to \$32

Financial news for VCYT dated on 2020-05-06: Veracyte Q1 EPS \$(0.240) Misses \$(0.200) Estimate, Sales \$31.122M Beat \$30.600M Estimate

Financial news for VCYT dated on 2020-05-06: The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle

Financial news for VCYT dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for VCYT dated on 2020-04-23: Veracyte, Yale Report Exclusive License Deal To Advance First Genomic Monitoring Testing For Idiopathic Pulmonary Fibrosis, No Terms Disclosed

Financial news for VCYT dated on 2020-04-21: Shares of several healthcare companies are trading lower with the overall market on continued downward momentum after oil prices fell to historic lows, partially stemming from weak demand caused by the coronavirus pandemic.

Financial news for VCYT dated on 2020-04-17: The Daily Biotech Pulse: Moderna Secures \$483M In BARDA Funding, Gilead Remdesivir Data, Veracyte's Positive Pre-Announcement

Financial news for VCYT dated on 2020-04-16: Veracyte To Withdraw Full-Year FY20 Guidance

Financial news for VCYT dated on 2020-04-16: Veracyte Sees Q1 Prelim. Sales \$30.5M-\$31.5M Vs. \$30.35M Est.

Financial news for VCYT dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest-stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for VCYT dated on 2020-03-18: Stocks That Hit 52-Week Lows On Wednesday

Financial news for VCYT dated on 2020-03-13: The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings

Financial news for VCYT dated on 2020-02-26: 10 Biggest Price Target Changes For Wednesday

Financial news for VCYT dated on 2020-02-26: Needham Maintains Buy on Veracyte, Lowers Price Target to \$30

Financial news for VCYT dated on 2020-02-25: Veracyte 8-K Shows Registration For Resale Of Up To ~376.7K Shares Of Common Stock To NanoString Technologies

Financial news for VCYT dated on 2020-02-25: Veracyte Sees FY20 Sales \$138M-\$142M vs \$136M Estimate

Financial news for VCYT dated on 2020-02-25: Veracyte Q4 EPS \$(0.15) Misses \$(0.07) Estimate, Sales \$29.73M Beat \$29.53M Estimate

Financial news for VCYT dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for VCYT dated on 2020-02-23: The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace

Financial news for VCYT dated on 2020-01-08: Veracyte Announces Biopharmaceutical Collaboration With Acerta Pharma

Financial news for VCYT dated on 2019-12-04: The Daily Biotech Pulse: Roche's Tecentriq Snags FDA Nod For Lung Cancer, Rapt Out-Licenses Cancer Drug

Financial news for VCYT dated on 2019-12-04: Nanostring Technologies Says on December

3, Co Entered Into a License & Asset Purchase Agreement With Veracyte; Co Granted to Veracyte Exclusive Worldwide License to Ncounter Flex Analysis System; Sold to Veracyte Certain Assets

Financial news for VCYT dated on 2019-12-03: Veracyte Acquires Exclusive License to NanoString Diagnostics Platform For \$40M In Cash And \$10M In Stock; Co. Sees \$6M-\$8M Revenue Contribution In 2020

Financial news for VCYT dated on 2019-11-03: Veracyte Announced New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer

Financial news for VCYT dated on 2019-10-30: Veracyte Highlights New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association

Financial news for VCYT dated on 2019-10-24: 41 Biggest Movers From Yesterday

Financial news for VCYT dated on 2019-10-22: Veracyte Reaffirms FY19 Sales Guidance Of \$119M-\$122M, Operating Activities Net Cash Of \$2M-\$4M

Financial news for VCYT dated on 2019-10-22: Veracyte Q3 EPS \$(0.02) Beats \$(0.07) Estimate, Sales \$31M Beat \$30.1M Estimate

Financial news for VCYT dated on 2019-10-22: The Daily Biotech Pulse: Biogen Alzheimer's Program Back On Track, Novartis Reports Strong Quarter, Takeda In-Licenses Autoimmune Disorder Drug

Financial news for VCYT dated on 2019-10-22: Veracyte Highlights New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis

Financial news for VCYT dated on 2019-10-21: Veracyte Highlights Data Showing Clinical Validity Of Next-Gen Percepta Classifier Will Be Presented At American College of Chest Physicians Thurs.

Financial news for VCYT dated on 2019-10-21: Veracyte Reports Data From 3 Studies Presented At American College of Chest Physicians Meeting Showing Envisia Improves Physicians' Ability To Diagnose Idiopathic Pulmonary Fibrosis

Financial news for VCYT dated on 2019-09-11: Veracyte Highlights Publication Of Clinical, Analytical Validation Data For Afirma Xpression Atlas

Financial news for VCYT dated on 2019-09-10: 50 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VCYT dated on 2019-09-03: Veracyte Highlights Publication Of New Study Characterizing Gene Alterations In Thyroid Cancer

Financial news for VCYT dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for VCYT dated on 2019-07-31: Benzinga's Top Upgrades, Downgrades For July 31, 2019

Financial news for VCYT dated on 2019-07-31: Lake Street Initiates Coverage On Veracyte with Buy Rating

Financial news for VCYT dated on 2019-07-30: Veracyte Raises FY19 Sales Guidance From \$117M-\$121M To \$119M-\$122M vs \$119.3M Estimate

Financial news for VCYT dated on 2019-07-30: Veracyte Q2 EPS \$(0.05) Beats \$(0.1) Estimate, Sales \$30.136M Beat \$28.84M Estimate

Financial news for VCYT dated on 2019-07-30: The Daily Biotech Pulse: European Cheer For Merck, Legal Victory For Coherus, Medpace Picks Up On Earnings

Financial news for VCYT dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for VCYT dated on 2019-07-24: 60 Biggest Movers From Yesterday

Financial news for VCYT dated on 2019-07-23: 45 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VCYT dated on 2019-07-23: The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation

Financial news for VCYT dated on 2019-07-02: Benzinga's Top Upgrades, Downgrades For July 2, 2019

Financial news for VCYT dated on 2019-07-02: Needham Initiates Coverage On Veracyte with Buy Rating, Announces \$33 Price Target

Financial news for VCYT dated on 2019-07-01: Veracyte Announces Keith Kennedy COO and CFO

Financial news for VCYT dated on 2019-06-26: Veracyte Reports Its Percepta Genomic Sequencing Classifier Now Available To Physicians

Financial news for VCYT dated on 2019-06-18: The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale

Financial news for VCYT dated on 2019-06-17: Veracyte Announces New Article Published in Cancer Cytopathology Detailing Clinical Utility of Its RNA Sequencing-Based Testing for Thyroid Cancer Diagnosis and Treatment

Financial news for VCYT dated on 2019-06-11: The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering

Financial news for VCYT dated on 2019-06-10: Veracyte Highlights Publication Of Data Showing 'Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis'

Financial news for VCYT dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for VCYT dated on 2019-06-03: Veracyte Sat. Announced New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis

Financial news for VCYT dated on 2019-06-03: 64 Biggest Movers From Friday

Financial news for VCYT dated on 2019-06-01: Veracyte Announces New Data Showing Potential of Afirma Genomic Test to Guide Targeted Treatment for Medullary Thyroid Cancer Concurrent with Diagnosis at #ASCO19

Financial news for VCYT dated on 2019-05-31: Shares of many healthcare companies are trading lower following a tweet from President Trump late Thursday stating the US will impose a 5 percent tariff on goods from Mexico.

Financial news for VCYT dated on 2019-05-23: Veracyte Highlights Will Present New Data Showing Afirma Xpression Atlas's Potential to Inform Treatment Selection for Patients with Medullary Thyroid Cancer At ASCO

Financial news for VCYT dated on 2019-05-02: Veracyte Prices Public Offering of 5.5M Shares of Common Stock at \$23.25/Share

Financial news for VCYT dated on 2019-05-02: The Daily Biotech Pulse: FDA Nod For Sanofi's Dengue Vaccine, Veracyte Offering, Biogen Reports Positive Data

Financial news for VCYT dated on 2019-05-02: 60 Biggest Movers From Yesterday

Financial news for VCYT dated on 2019-05-01: Veracyte Reports 5M Share Common Stock Offering

Financial news for VCYT dated on 2019-05-01: 46 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VCYT dated on 2019-05-01: Veracyte Reported Tues. Afternoon Q1 EPS \$(0.05) Beats \$(0.1) Estimate, Sales \$29.529M Beat \$27.61M Estimate

Financial news for VCYT dated on 2019-05-01: The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue

Financial news for VCYT dated on 2019-04-30: The Daily Biotech Pulse: Earnings Deluge, G1 Therapeutics Positive FDA Meeting, Mustang Bio Offering

Financial news for VCYT dated on 2019-04-23: The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale

Financial news for VCYT dated on 2019-04-22: Veracyte Reports Received Regulatory Authorization To Offer Envisia Genomic Classifier For Patients In State Of New York

Financial news for VCYT dated on 2019-04-02: Veracyte Announces Data Published in The Lancet Respiratory Medicine Demonstrate that the Envisia Genomic Classifier Improves

Diagnosis of IPF

Financial news for VCYT dated on 2019-03-26: The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

Financial news for VCYT dated on 2019-03-25: Veracyte Highlights New Afirma Xpression Atlas Data Presented At ENDO 2019 Conference

Financial news for VCYT dated on 2019-03-22: The Daily Biotech Pulse: Immutept Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback

Financial news for VCYT dated on 2019-03-21: The Daily Biotech Pulse: Biogen Plummets, FDA Greenlights Sleep Disorder Drug, Cellular Biomedicine Offering

Financial news for VCYT dated on 2019-03-18: Veracyte To Present Afirma Xpression Atlas Data On Medullary Thyroid Cancer To Be Presented At ENDO 2019

Financial news for VCYT dated on 2019-03-06: Shares of several biotech companies are trading lower after FDA commissioner Scott Gottlieb announced he will resign; he pushed to spur the development of new drugs and with his absence, there is concern on future FDA approvals.

Financial news for VCYT dated on 2019-03-04: Veracyte Receives Final Medicare Coverage Policy For Envisia Genomic Classifier

Financial news for VCYT dated on 2019-02-27: The Daily Biotech Pulse: FDA Panel Vote Sinks KaryoPharm, Refuse-To-file Letter For Adamis, Tandem Diabetes Earnings

Financial news for VCYT dated on 2019-02-26: The Daily Biotech Pulse: Immunomedics CEO Departs, Ultragenyx Offering, Karyopharm Awaits FDA Panel Vote

Financial news for VCYT dated on 2019-02-25: Veracyte Q4 EPS \$(0.08) Beats \$(0.15) Estimate, Sales \$25.75M Beat \$24.36M Estimate

Financial news for VCYT dated on 2019-02-25: Veracyte Q4 Earnings Preview

Financial news for VCYT dated on 2019-02-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs

Financial news for VCYT dated on 2019-02-05: The Daily Biotech Pulse: Gilead Earnings, Codexis Sings Pact With Merck, Eli Lilly Reports Positive Trial Results

Financial news for VCYT dated on 2019-02-01: The Daily Biotech Pulse: Merck Earnings, Positive Relaunch Of Titan's Opioid Disorder Treatment Implant

Financial news for VCYT dated on 2019-01-23: The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study

Financial news for VCYT dated on 2019-01-11: Stocks Which Set New 52-Week High Yesterday, Thurs., Jan. 10, 2019

Financial news for VCYT dated on 2019-01-11: The Daily Biotech Pulse: Agile Gives Regulatory Update On Contraceptive Patch, Advaxis Misses Estimates, Ocular Submits sNDA

Financial news for VCYT dated on 2019-01-04: 58 Biggest Movers From Yesterday

Financial news for VCYT dated on 2019-01-03: 44 Stocks Moving In Thursday's Mid-Day Session

Financial news for VCYT dated on 2019-01-03: Veracyte shares are trading up after the company announced a strategic collaboration with J&J Innovation for lung cancer detection.

Financial news for VCYT dated on 2019-01-03: UPDATE: Veracyte Reports Will Combine Clinical Study Cohorts Involving 5K+ Patients, Multiple Years Of Clinical Outcome Data

Financial news for VCYT dated on 2019-01-03: Veracyte Reports Strategic Collaboration With J&J Innovation For Lung Cancer Detection

Financial news for VCYT dated on 2018-11-29: Benzinga's Top Upgrades, Downgrades For November 29, 2018

Financial news for VCYT dated on 2018-11-29: Janney Capital Downgrades Veracyte to Neutral

Financial news for VCYT dated on 2018-11-13: 70 Biggest Movers From Yesterday

Financial news for VCYT dated on 2018-11-12: 54 Stocks Moving In Monday's Mid-Day Session

Financial news for VCYT dated on 2018-11-05: 74 Biggest Movers From Friday

Financial news for VCYT dated on 2018-11-02: 64 Stocks Moving In Friday's Mid-Day Session

Financial news for VCYT dated on 2018-11-01: Stocks Which Set New 52-Week High Yesterday, October 31st

Financial news for VCYT dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for VCYT dated on 2018-11-01: 82 Biggest Movers From Yesterday

Financial news for VCYT dated on 2018-10-31: 66 Stocks Moving In Wednesday's Mid-Day Session

Financial news for VCYT dated on 2018-10-31: 64 Biggest Movers From Yesterday

Financial news for VCYT dated on 2018-10-30: Mid-Afternoon Market Update: Crude Oil Down 1.8%; Veracyte Shares Jump After Q3 Results

Financial news for VCYT dated on 2018-10-30: 55 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VCYT dated on 2018-10-30: Mid-Day Market Update: Dow Rises Over 200 Points; Electro Scientific Industries Shares Spike Higher

Financial news for VCYT dated on 2018-10-30: Mid-Morning Market Update: Markets Open Higher; General Electric Misses Q3 Expectations

Financial news for VCYT dated on 2018-10-29: Veracyte Raises FY18 Sales Guidance From \$87M-\$89M To \$90M-\$91M vs \$88.09M Est., Reduces Annual Cash Burn Guidance From \$18M-\$21M To \$17M-\$18M

Financial news for VCYT dated on 2018-10-29: Veracyte Q3 EPS \$(0.12) Beats \$(0.25) Estimate, Sales \$23.466M Beat \$21.5M Estimate

Financial news for VCYT dated on 2018-10-29: Q3 Earnings Preview For Veracyte

Financial news for VCYT dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for VCYT dated on 2018-10-09: The Daily Biotech Pulse: Affirmed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial

Financial news for VCYT dated on 2018-10-07: Veracyte Announces New Data from Multiple Studies Demonstrate "Real World" Performance of Afirma GSC and Xpression Atlas in Thyroid Cancer Diagnosis

Financial news for VCYT dated on 2018-09-27: Veracyte To Present New Data Highlighting The Ability Of Percepta Bronchial To Reduce Invasive Procedures At CHEST Annual Meeting

Financial news for VCYT dated on 2018-09-04: Stocks Which Set New 52-Week High Friday, August 31

Financial news for VCYT dated on 2018-08-31: Stocks Which Set New 52-Week High Yesterday, August 30th

Financial news for VCYT dated on 2018-08-31: The Daily Biotech Pulse: FDA Blessings for Merck's HIV Drug Combo, Veracyte's Test Gets Medicare Coverage

Financial news for VCYT dated on 2018-08-30: UPDATE: Veracyte Says Received Draft Medicare Local Coverage Determination For Envisia Genomic Classifier Through MolDx Program

Financial news for VCYT dated on 2018-08-30: Veracyte Highlights Medicare Milestone For Envisia Genomic Classifier

Financial news for VCYT dated on 2018-08-27: Stocks Which Set New 52-Week High Friday, August 24th

Financial news for VCYT dated on 2018-08-17: Stocks Which Set New 52-Week High Yesterday, August 16th

Financial news for VCYT dated on 2018-08-16: Stocks Which Set New 52-Week High Yesterday, August 15th

Financial news for VCYT dated on 2018-08-10: Stocks Which Set New 52-Week High Yesterday, August 9th

Financial news for VCYT dated on 2018-08-10: The Daily Biotech Pulse: Puma, CareDx Soar On Earnings, Corcept Plunges On Bottom-Line Miss

Financial news for VCYT dated on 2018-08-06: Stocks Which Set New 52-Week Highs Friday, August 3rd

Financial news for VCYT dated on 2018-08-03: Stocks Which Set New 52-Week High Yesterday, August 2nd

Financial news for VCYT dated on 2018-07-26: Veracyte Late Wednesday Announced Pricing Of 5M Share Common Stock Offering At \$10.25/Share

Financial news for VCYT dated on 2018-07-25: Stocks Which Set New 52-Week High Yesterday, July 24th:

Financial news for VCYT dated on 2018-07-25: Benzinga's Daily Biotech Pulse: Merck's Keytruda Found Effective, Nabriva To Acquire Zavante, FDA Denies Agile

Financial news for VCYT dated on 2018-07-25: 46 Biggest Movers From Yesterday

Financial news for VCYT dated on 2018-07-24: Veracyte Reports Offering Of 5M Common Shares

Financial news for VCYT dated on 2018-07-24: 34 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VCYT dated on 2018-07-24: Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering

Financial news for VCYT dated on 2018-07-23: Veracyte Raises FY18 Sales Outlook From \$83M-\$86M To \$87M-\$89M vs \$84.54M Est.

Financial news for VCYT dated on 2018-07-23: Veracyte Raises FY18 Sales Guidance

Financial news for VCYT dated on 2018-07-23: Veracyte Q2 EPS \$(0.18) Beats \$(0.27) Estimate, Sales \$22.8M Beat \$20.56M Estimate

Financial news for VCYT dated on 2018-07-23: Earnings Preview: Veracyte

Financial news for VCYT dated on 2018-07-22: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for VCYT dated on 2018-07-10: Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

Financial news for VCYT dated on 2018-07-05: Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index

Financial news for VCYT dated on 2018-05-23: Veracyte Highlights Clinical Validation Data Published In JAMA Surgery Showed Afirma Genomic Sequencing Classifier Identified At Least 1/3 More Benign Thyroid Nodules Among Those Deemed Indeterminate By Cytopathology

Financial news for VCYT dated on 2018-05-23: UBS Global Healthcare Conference 2018 Concludes Today With Presenters Including Quidel and Veracyte

Financial news for VCYT dated on 2018-05-23: 38 Biggest Movers From Yesterday

Financial news for VCYT dated on 2018-05-01: Veracyte Raises FY2018 Sales Guidance from \$81.0M-83.0M to \$83.0M-86.0M vs \$89.80M Est

Financial news for VCYT dated on 2018-05-01: Veracyte Raises FY18 Sales Outlook

Financial news for VCYT dated on 2018-05-01: Veracyte Q1 EPS \$(0.27), Made \$20.041M Sales

Financial news for VCYT dated on 2018-05-01: Veracyte S-3 Shows Registration For \$125M Mixed Securities Shelf Offering

Financial news for VCYT dated on 2018-04-11: Veracyte Reports Precision Medicine Collab With Loxo Oncology, 'Leverages Veracyte's New Afirma Xpression Atlas Platform'

Financial news for VCYT dated on 2018-03-14: Veracyte To Unveil New Afirma Xpression Atlas Program At ENDO '18

Financial news for VCYT dated on 2018-02-27: Veracyte Sees FY18 Sales \$81M-\$83M vs \$85M Est.

Financial news for VCYT dated on 2018-02-27: Veracyte Reports Q4 EPS \$(0.24) vs \$(0.20) Est., Sales \$19.596M vs \$19M Est.

Financial news for VCYT dated on 2018-02-27: Veracyte Q4 Earnings Preview

Financial news for VCYT dated on 2018-01-18: UPDATE: Veracyte Says '61% endured an invasive procedure for diagnosis'

Financial news for VCYT dated on 2018-01-18: Veracyte Reports Results Of Patient Survey Quantifying Challenges In Diagnosing Interstitial Lung Disease: '55% of participants in national Pulmonary Fibrosis Foundation survey reported at least one misdiagnosis'

Financial news for VCYT dated on 2018-01-08: UPDATE: Veracyte Reports Will Consolidate Clinical, Medical, R&D Functions Into 1 Department

Financial news for VCYT dated on 2018-01-08: Veracyte Company Reiterates 2017 Revenue Of \$71-\$72M and Cash Burn Guidance Of \$25M to \$26M, Announces Strategic Realignment and New Appointments to Advance Commercial Growth

Financial news for VCYT dated on 2017-11-28: Veracyte Reports Publication of Data Confirming Analytical Validity of Envisia Genomic Classifier for Use in IPF Diagnosis

Financial news for VCYT dated on 2017-11-08: 56 Biggest Movers From Yesterday

Financial news for VCYT dated on 2017-11-07: 45 Stocks Moving In Tuesday's Mid-Day Session

Financial news for VCYT dated on 2017-11-07: Veracyte Shares Resume Trade, Continue Lower, Now Down 23.7%

Financial news for VCYT dated on 2017-11-07: Veracyte Shares Halted On Circuit Breaker, Down 20%; Stock To Resume Trade At 9:35:18 a.m. EST

Financial news for VCYT dated on 2017-11-07: Benzinga's Top Upgrades, Downgrades For November 7, 2017

Financial news for VCYT dated on 2017-11-07: Janney Capital Downgrades Veracyte to Neutral

Financial news for VCYT dated on 2017-11-06: Veracyte Sees FY17 Sales \$71-\$72M vs \$76M Est.

Financial news for VCYT dated on 2017-11-06: Veracyte Reports Q3 EPS \$(0.20) vs \$(0.23) Est., Sales \$17.5M vs \$19.5M est.

Financial news for VCYT dated on 2017-11-01: UPDATE: Veracyte To Show 'Greater Than 50% Reduction in Patients [Using Percepta] Classified as Low Risk for Lung Cancer

Financial news for VCYT dated on 2017-11-01: Veracyte Will Present New Clinical Utility Data At CHEST '17 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis

Financial news for VCYT dated on 2017-10-22: Veracyte Announces New Data Highlighting Performance of the Afirma GSC Ensemble Machine Learning Algorithms in Challenging Thyroid Cancer Subtypes to Be Presented at ATA Next-Generation Test is First to Distinguish Benign from Cancerous Hurthle Cells

Financial news for VCYT dated on 2017-09-25: Veracyte Reports Reimbursement Rate From Afirma Is Expected To Increase From \$3,200 To \$3,600 For Calendar Year '18

Financial news for VCYT dated on 2017-08-31: BTIG Transitions Coverage Of Veracyte, Establishes Buy Rating And \$13 Price Target

Financial news for VCYT dated on 2017-07-31: Veracyte Reports Q2 EPS \$(0.22) vs \$(0.25) Est., Sales \$18.4M vs \$18.33M Est.

Financial news for VCYT dated on 2017-07-31: UPDATE: Veracyte Says 'Enhanced Classifier Identifies 30% More Benign Patients Than Original, Flagship Test'

Financial news for VCYT dated on 2017-07-31: Veracyte Reports Pivotal Clinical Validation Data For Afirma Genomic Sequencing Classifier

Financial news for VCYT dated on 2017-07-26: Veracyte Reports Positive Data From 3 Afirma Studies to Be Presented at World Congress on Thyroid Cancer, Oral Presentation Highlights Next-Generation Afirma Genomic Sequencing Classifier

Financial news for VCYT dated on 2017-05-23: Veracyte Announces Clinical Data From Envisia Pivotal Study, Confirms Evisia's Ability To Detect UIP

Financial news for VCYT dated on 2017-05-03: Veracyte Reports Q1 EPS \$(0.24) vs \$(0.25) Est., Sales \$16.432M vs \$17.69M Est.

Financial news for VCYT dated on 2017-03-01: Veracyte Sees FY17 Sales \$76M-\$84M vs \$80.3M Est.

Financial news for VCYT dated on 2017-03-01: Veracyte Reports Q4 EPS \$(0.14) vs \$(0.26) Est., Sales \$18.257M vs \$17.5M Est.

Financial news for VCYT dated on 2017-02-27: Veracyte Reports Publication of Data Demonstrating Potential for Non-Invasive Nasal Test to Improve Lung Cancer Diagnosis

Financial news for VCYT dated on 2017-02-17: Veracyte Afirma Now Considered Medically Appropriate By Blue Cross Blue Shield of Tennessee

Financial news for VCYT dated on 2017-02-08: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for VCYT dated on 2017-02-08: Veracyte Reports Will Extend Access to Its Afirma GEC Through Deal with Quest Diagnostics

Financial news for VCYT dated on 2017-02-06: Veracyte's Percepta to be Covered by Medicare Administrative Contractor Palmetto

Financial news for VCYT dated on 2016-11-29: Benzinga's Top Upgrades

Financial news for VCYT dated on 2016-11-29: Janney Capital Upgrades Veracyte to Buy

Financial news for VCYT dated on 2016-11-22: Veracyte Says the Centers for Medicare and Medicaid Will Allow the Test Rate of \$3,200 To Remain in 2017

Financial news for VCYT dated on 2016-11-21: Veracyte Announces Keith Kennedy CFO